Security National Bank of Sioux City Iowa IA Purchases 6,268 Shares of Abbott Laboratories $ABT

Security National Bank of Sioux City Iowa IA raised its position in Abbott Laboratories (NYSE:ABT) by 34.9% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 24,246 shares of the healthcare product maker’s stock after buying an additional 6,268 shares during the quarter. Security National Bank of Sioux City Iowa IA’s holdings in Abbott Laboratories were worth $2,200,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Cornerstone Financial Management LLC bought a new position in Abbott Laboratories in the fourth quarter valued at approximately $25,000. MidAtlantic Capital Management Inc. bought a new stake in Abbott Laboratories during the fourth quarter worth $25,000. Purpose Unlimited Inc. acquired a new stake in shares of Abbott Laboratories in the 4th quarter valued at $25,000. Portfolio Resources Advisor Group Inc. acquired a new stake in shares of Abbott Laboratories in the 4th quarter valued at $26,000. Finally, Abound Financial LLC bought a new position in shares of Abbott Laboratories in the 4th quarter valued at $26,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Trading Up 0.1%

ABT traded up $0.12 during trading on Friday, reaching $102.35. 27,061,539 shares of the company’s stock were exchanged, compared to its average volume of 11,547,542. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The firm has a fifty day moving average price of $106.18 and a two-hundred day moving average price of $99.38. The stock has a market capitalization of $177.11 billion, a PE ratio of 33.12, a price-to-earnings-growth ratio of 1.90 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities research analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 annualized dividend and a yield of 2.5%. Abbott Laboratories’s payout ratio is presently 81.55%.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on ABT shares. Weiss Ratings upgraded Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, August 6th. BTIG Research boosted their target price on Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. JPMorgan Chase & Co. increased their target price on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. TD Cowen restated a “buy” rating and issued a $135.00 price target on shares of Abbott Laboratories in a research note on Tuesday, September 8th. Finally, Robert W. Baird began coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $119.50.

About Abbott Laboratories

Abbott Laboratories (NYSE: ABT) is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company’s medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.